Pasithea Therapeutics Corp. KTTA 深 滬
已收盤 11-06 16:00:00 美东时间
0.5788
+0.059
+11.31%
華盛通- 最 高0.5799
- 今 開0.5085
- 成交量 43.69万股
- 最 低 0.5051
- 昨 收 0.52
- 總市值 1934.03万
- 52周最高 2.06
- 市盈率 靜 --
- 換手率 1.31%
- 52周最低 0.281
- 委 比 39.02%
- 總股本 3341.44万
- 歷史最高 170.00
- 量 比 0.09
- 振 幅 14.38%
- 歷史最低 0.281
- 每 手 1
- 風險率 0.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pasithea Therapeutics Says FDA Clears IND Application For Randomized, Placebo-Controlled Phase 2 Clinical Trial For PAS-004 In Patients With NF1 Associated Cutaneous Neurofibromas
— FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies. — MIAMI, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "...
11-03 20:04
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
Pasithea Therapeutics Corp. announced FDA clearance for its IND application to conduct a Phase 2 clinical trial of PAS-004 for NF1-associated cutaneous neurofibromas (cNF), a condition affecting over 95% of NF1 patients with no FDA-approved systemic therapies. PAS-004, a next-generation oral MEK inhibitor, aims to address this unmet need with its long half-life and chronic dosing potential. The Phase 2 study will evaluate its safety, efficacy, an...
11-03 12:00
Pasithea Therapeutics Presents Phase I Dose-Escalation Trial Of PAS-004 Inhibitor; Announces No Dose Limiting Toxicities Seen; No Participant Discontinued PAS-004; No Grade 3, Higher Observed
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, today announced updated safety, tolerability, and preliminary efficacy data from its ongoing Phase 1 dose-escalation s...
10-23 21:20
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Pasithea Therapeutics Corp. announced updated data from its Phase 1 study of PAS-004, a next-gen MEK inhibitor, showing prolonged stable disease in heavily pre-treated patients, including two with BRAF V600E melanoma on treatment for over 500 days. PAS-004 demonstrated favorable safety, with no Grade 3+ adverse events or discontinuations, and a long half-life supporting once-daily dosing. The data highlight durable clinical benefit and tolerabili...
10-23 13:15
Pasithea Sets November Debut For Early PAS-004 Clinical Trial Results
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1)-associated neurofibromas, tod...
09-14 19:08
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Pasithea Therapeutics Corp. will present initial clinical data from its Phase 1/1b trial of PAS-004 for neurofibromatosis type 1 (NF1) at the 2026 European Neurofibromatosis Conference in Vienna, Austria. The data on cutaneous neurofibromas (CN) will be presented orally by Rebecca Brown, MD, while plexiform neurofibromas (PN) data will be showcased in a poster by Tiago Reis Marques, CEO of Pasithea. The conference will take place November 12–14, ...
09-14 11:00
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Pasithea Therapeutics Corp. will participate in two investor conferences in September 2026: the 12th Annual Cantor Global Healthcare Conference (September 9-11) and the H.C. Wainwright 28th Annual Global Investment Conference (September 14-16). Management will hold one-on-one investor meetings at Cantor Global and present at H.C. Wainwright on September 14, 2026, at 2:30 PM ET. The Company is developing PAS-004, a next-generation macrocyclic oral...
09-03 20:05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
Pasithea Therapeutics Corp. announced that an abstract detailing the Phase 1 dose-escalation study of PAS-004, a next-generation macrocyclic MEK inhibitor, in patients with MAPK pathway-driven advanced solid tumors, has been accepted for poster presentation at the ESMO Congress 2026. The presentation will occur on Friday, October 23, 2026, and the full abstract will be published on the ESMO website under the congress' embargo policy. PAS-004 is b...
07-21 11:00
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Pasithea Therapeutics Corp. announced that its management will participate in the Mind, Muscle & Vision Summit on July 16, 2026, in Boston. The event, hosted by B. Riley Securities, focuses on neuropsychiatry, neurodegeneration, neuromuscular diseases, ophthalmology, and neuroimmunology. Pasithea will engage with investors and industry participants to discuss PAS-004, a next-generation macrocyclic MEK inhibitor for treating chronic diseases like ...
07-08 11:02
Pasithea Therapeutics Announces Updated Interim Safety And Clinical Activity Data From Its Trial Evaluating PAS-004 In Patients With MAPK Pathway-Driven Advanced Solid Tumors; PAS-004 Has Been Well-Tolerated, With All Treatment-Related Adverse Events Being Grade 1 Or 2
Pasithea Therapeutics Corp. (NASDAQ:KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including the neurocutaneous manifestations of neurofibromatosis type ...
06-30 19:04
